HK
CSCI

Horizon Kinetics’s COSCIENS Biopharma Inc. Common Stock CSCI Stock Holding History

Horizon Kinetics’s Portfolio CSCI Stock Details CSCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-2
Closed -$26K – 553
2013
Q3 		$26K Hold
2
– – ﹤0.01% 539
2013
Q2 		$32K Buy
+2
New +$37.9K ﹤0.01% 458

Other funds holding CSCI

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
AG
Aperio Group Sausalito, California $33.8B AUM 31.46% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Horizon Kinetics's CSCI Position: Q4 2013 in Review

Horizon Kinetics sold out of COSCIENS Biopharma Inc. Common Stock (CSCI) in Q4 2013, closing a stake of 2 shares — an estimated $26K sold.

Horizon Kinetics first reported a position in CSCI in Q2 2013 and held it in 2 quarters. The position peaked at $32K in Q2 2013. 12 funds tracked by Wall St. Rank hold CSCI as of Q4 2013.

  • Horizon Kinetics reported no remaining COSCIENS Biopharma Inc. Common Stock position as of Q4 2013 after selling out during the quarter.
  • Horizon Kinetics sold 2 COSCIENS Biopharma Inc. Common Stock shares in Q4 2013, an estimated $26K.
  • Horizon Kinetics first reported a position in COSCIENS Biopharma Inc. Common Stock in Q2 2013 and held it in 2 quarters.
  • Horizon Kinetics's COSCIENS Biopharma Inc. Common Stock position peaked at $32K in Q2 2013.
  • 12 funds tracked by Wall St. Rank held COSCIENS Biopharma Inc. Common Stock as of Q4 2013.

Based on Horizon Kinetics's 13F filing for Q4 2013, filed 13 Feb 2014.